Arti Muley, Aditi Deshmane, Anu Mahajan, Jeel Shah
Eating Disorders: Assessing Its Prevalence and Pattern Among Adults With Type 2 Diabetes
Cureus
biosimilars reduce burden cost patients payers increase access lifesaving care however biosimilar uptake us inconsistent study assessed provider perceptions barriers biosimilar use relationships utilization rates large national oncology network examined perceptions differed demographic practice characteristics 28item survey administered 400 network physicians pharmacists nurses administrators spanning 25 provider groups measured 1 barriers use categorized 4 subscalespayerrelated providerrelated operational patientrelated using likert scale ranging never 1 always 5 2 demographic practice characteristics utilization rates assessed using aggregated patientlevel drug administration data found electronic health record system descriptive inferential statistics used describe responses assess relationships variables total 46 responses analyzed response rate 115 respondents female 556 physicians 522 6 years experience 67 majority worked practices participating oncology care model 867 received continuing education biosimilars 848 overall scale score moderately low mean231 indicating low levels perceived barriers lowest subscale score operational barriers mean221 payerrelated barriers highest mean278 perceptions barriers differ based demographic practice characteristics average biosimilar utilization rate 662 practices west administering biosimilars frequently 718 utilization impacted perceptions barriers perceived barriers biosimilar utilization common associated utilization infrequent impediments utilization may associated networkwide emphasis continuing education valuebased care environment future research consider practice patientlevel factors may impact biosimilar utilization